

20 March 2024

ASX Announcement

INOVIQ STRENGTHENS EXOSOME LEADERSHIP WITH NEW PATENT APPLICATION

INOVIQ Limited (ASX:IIQ or **INOVIQ**) is pleased to announce that it has expanded its exosome intellectual property (IP) portfolio by filing an Australian Provisional Patent Application (APPA) covering its cutting-edge EXO-ACE technology for large scale isolation of exosomes for therapeutic use. The APPA covers compositions for use in capturing extracellular vesicles for large scale commercial applications.

INOVIQ is leveraging its technology and capabilities in exosome science to progress its next generation exosome therapeutics program using exosomes from immune cells to target and treat cancer.

This patent application will protect INOVIQ's new EXO-ACE technology for large scale isolation of exosomes. In studies completed to date, EXO-ACE has demonstrated outstanding results, with over 80% recovery and 95% purity of exosomes isolated from immune cells, that are being evaluated in INOVIQ's exosome therapeutics program.

Exosomes are small vesicles released by all cell types, including immune cells such as T-cells and Natural Killer (NK)-cells. INOVIQ's exosome therapeutics program utilises exosomes released from immortalised CAR-T and CAR-NK cells. CAR-T and CAR-NK cells are genetically engineered immune cells that express a chimeric antigen receptor (CAR). These receptors enable CAR-T/NK cells to specifically recognize and bind to cancer cells based on surface antigens and release their cytotoxic effects.

Exosomes released by CAR-T/NK cells have enormous potential as cell-free therapeutics, with potential manufacturing and safety advantages over autologous cell therapies. These exosomes inherit the same tumour-targeting and cytotoxic capabilities as their parent CAR-T/NK cells, specifically targeting and killing cancer cells.

Chairman David Williams said: *"INOVIQ is strengthening its leadership in next generation exosome diagnostics and therapeutics with this patent. This latest application strengthens and protects our cutting-edge EXO-ACE technology that enables large-scale production of exosomes for INOVIQ's exosome therapeutics program.*

INOVIQ's EXO-NET technology is recognised worldwide with Promega Corporation as a valued commercial co-marketing partner and biopharmaceutical companies evaluating EXO-NET to develop companion diagnostics for patient stratification and monitoring of targeted therapeutics."

Authorised for release by the Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.